Dr Zhou on Frontline Ivonescimab vs Pembrolizumab in PD-L1+ Advanced NSCLC

9 months ago 54

Caicun Zhou, MD, PhD, discusses data for ivonescimab vs pembrolizumab as first-line treatment for patients with PD-L1–positive advanced NSCLC.

1. Homepage
2. Lung Cancer
3. Dr Zhou on Frontline Ivonescimab vs Pembrolizumab in PD-L1+ Advanced NSCLC